The proliferation of M-NFS-60 cells treated with increasing concentrations of mM-CSF was assessed. After 48 hour treatment with mM-CSF, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant mM-CSF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mM-CSF and staining overnight with Coomassie Blue.
Western blot analysis of extracts from M-NFS-60 cells, untreated or treated with mM-CSF for 10 minutes, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370 (upper) and p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (lower).
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mM-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mM-CSF. All lots are greater than 98% pure.
Less than 0.01 ng endotoxin/1 μg mM-CSF.
The bioactivity of recombinant mM-CSF was determined in an M-NFS-60 cell proliferation assay. The ED50 of each lot is between 0.5-2.0 ng/ml.
Recombinant mM-CSF contains no "tags" and the nonglycosylated protein has a calculated MW of 25,987. DTT-reduced protein migrates as a 37-50 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 55-80 kDa protein. Heterogeneity and lower mobility in SDS-PAGE are due to glycosylation. The expected amino-terminal KEVSE of recombinant mM-CSF was verified by amino acid sequencing.
Recombinant mouse M-CSF (mM-CSF) Lys33-Glu262 (Accession #NP_031804) was expressed in human 293 cells at Cell Signaling Technology.
Macrophage-colony stimulating factor (M-CSF) is produced by fibroblasts, endothelial cells, stromal cells, macrophages, osteoblasts, and other cell types (1). M-CSF is required for growth and differentiation of monocytes and macrophages (1,2). M-CSF polarizes macrophages into the M2 phenotype where anti-inflammatory IL-10 is produced, rather than the M1 phenotype where inflammatory cytokines are produced. M-CSF also recruits monocytes and enhances angiogenesis by inducing VEGF production (1,2). M-CSF binds to its receptor CSF1R; downstream signaling involves PI3K/Akt, Erk, and Stats 1, 3, and 5 (1,3). An increase in M-CSF expression may contribute to cancer progression, and high plasma M-CSF levels are associated with rheumatoid arthritis (1,4,5).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.